Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suzetrigine in Diabetic Peripheral Neuropathic Pain
NCT07231419Phase 3Recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic polyneuropathy (DPN) comparing Suzetrigine (SUZ) with Placebo (2 arms). Primary endpoint: Numeric Pain Rating Scale at 12 weeks. Started Nov 2025; status: recruiting.
02
Drugs
suzetrigine
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT07231419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07231419.